Breadcrumb Home Business Activities Lundbeckfonden BioCapital Lundbeckfonden BioCapital Portfolio Syntaxin Syntaxin Syntaxin developed bacterial-based protein therapeutics that inhibit cell secretion for the treatment of neurological, inflammatory and endocrine diseases. Lundbeckfonden BioCapital Invested 2010 Acquired by Ipsen in 2013 Location Abingdon, United Kingdom